Seeking Alpha

Vertex Pharmaceuticals (VRTX +4.8%) finishes higher today after saying it's entered into a...

Vertex Pharmaceuticals (VRTX +4.8%) finishes higher today after saying it's entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a Phase 2 study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue hepatitis C virus polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805. The study is expected to begin in early 2013, pending discussions with regulatory authorities.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs